Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
VVOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.91 - $6.28
Previous CloseN/A
Volume144.69K
Average Volume (3M)117.97K
Market Cap
$15.02M
Enterprise Value$20.52M
Total Cash (Recent Filing)$469.35K
Total Debt (Recent Filing)$3.71M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
May 19, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding5,889,520
10 Day Avg. Volume95,753
30 Day Avg. Volume117,969
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.19
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.48
Enterprise Value/Ebitda-1.70
Forecast
1Y Price Target
$5.50Price Target Upside115.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Vivos Therapeutics News
PremiumCompany Announcements
Vivos Therapeutics’ Earnings Call Highlights Growth and ExpansionPremiumCompany Announcements
Vivos Therapeutics Reports Revenue Growth and Strategic Shift
PremiumCompany Announcements
Vivos Therapeutics Enters Market Offering Agreement with Wainwright
---
Ownership Overview
1.24%
Insiders
0.45% Mutual Funds
4.77% Other Institutional Investors
93.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $1.91 and its highest was $6.28 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $15.02M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is May 19, 2025 which is in 41 days.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on Mar 31, 2025. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.77.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Undervalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 5,889,520 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of $0.41 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -7.719%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
---
Vivos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (115.69% Upside)
$5.50 (115.69% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.78%
12-Months-Change
Fundamentals
Return on Equity
-266.25%
Trailing 12-Months
Asset Growth
42.44%
Trailing 12-Months
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. is a healthcare company focused on addressing sleep and breathing disorders, particularly obstructive sleep apnea (OSA). The company operates within the medical technology and healthcare sectors, offering a proprietary system of oral appliances and related technologies designed to treat mild-to-moderate OSA and sleep-disordered breathing. Vivos emphasizes a multidisciplinary treatment approach, integrating dental and medical practices to provide comprehensive patient care.
---
VVOS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for Vivos Therapeutics, highlighting significant revenue growth, strategic market expansion, and successful business model pivot. Despite some challenges with decreased VIP enrollment revenue and ongoing cash flow needs, the overall sentiment is optimistic due to strong financial backing and regulatory advancements.Read More>---
VVOS Stock 12 Month Forecast
Average Price Target
$5.50
▲(115.69% Upside)
Technical Analysis
Orthofix
―
Zimmer Biomet Holdings
―
Semler Scientific
―
NovoCure
―
Irhythm Technologies
―
Best Analysts Covering VVOS
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-28.94%
reiterated a buy rating 5 months ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -28.94% per trade.
---